Professor David Masopust and Dr Alain Rolland joins PathoVax's Advisory Board.

June 11, 2019

PathoVax is pleased to announce the appointment of Dr. Alain Rolland and Professor David Masopust to our business and scientific advisory boards respectively, bringing years of business and scientific experience to guide PathoVax in further developing our lastest therapeutic strategy IMMUNE REDIRECTION


Dr. Rolland brings over 30 years of international leadership experience in pharmaceutical and biotech companies and is currently Vice President & Chief Development Officer of Emerald Health Pharmaceuticals (EHP). Prior to EHP, Dr. Rolland was a co-founder and served as CEO, President and Director of CHIME BioTherapeutics, Executive Vice President and Chief Scientific Officer at HUYA Bioscience International, Executive Vice President, Product Development at Vical, and Senior Vice President, Preclinical R&D, Head of The Woodlands Center of Valentis.

Professor Masopust is currently a Professor of Immunology and Microbiology at the University of Minnesota. He is an established leader in the field of T-cell immune memory having published in prestigious journals such as Nature, Cell and Science. He has also earned numerous accolades that recognize his work. Examples include NIH Director's New Innovator Award, American Society for Microbiology ICAAC Young Investigator Award and the Beckman Foundation Young Investigator Award. More recently, the Howard Huges (HHMI) Faculty Scholar award. Most recently, he published a seminal paper demonstrating pivotal proof of concept that viral responses can be re-purposed for immunotherapy thereby independently validating and complementing PathoVax's existing data on this innovative therapeutic strategy.

PathoVax joins the JLAB's family!

May 14, 2019

PathoVax LLC is back in Boston as part of the @JLABS family at #JPODSBoston. We look forward to continuing growing our presence in this innovative hub!

PathoVax's founder and CEO named Top 10 CEO in Baltimore biotech start up scene

April 10, 2019

March Madness! PathoVax LLC secures another NCI SBIR Phase 1 worth $300K as well as acceptance for Late Breaking Abstract for upcoming 2019 American Association for Cancer Research Annual Meeting

March 12, 2019

Two pieces of great news this Mid-March! First off, PathoVax has secured another SBIR Phase 1 worth $300K from the NCI to imbue thermostable and single-dose properties into our existing RGVax HPV vaccine. This new formulation will potentiate the world’s 1st single- immunization, thermostable, broad-spectrum Human Papillomavirus (HPV) Vaccine!!

Secondly, We will be presenting long term pre-clinical protection data in a Late-Breaking Abstract Poster session at the upcoming 2019 American Association for Cancer Research Annual Meeting!!!

PathoVax expands team with several key strategic appointments.

February 06, 2019

We are pleased to announce the appointment of industry experts Dr John Troyer Ph.D. and Dr Wenbin Lai, Ph.D., MBA to our Management and Operations advisory board. 

 

Dr. Troyer will assume the role of Chief Operations​ and brings over twenty five years of experience in multiple aspects of biologics and drug development from discovery to registration and commercial operations in various companies such as Pharmathene and ICON PLC. Specifically, he has overseen over 36 INDs, NDAs, BLAs and supervised a variety of Orphan Drug and FDA Fast-track applications/regulatory filings. Dr Troyer obtained his BS from Old Dominion University and Ph.D. from Eastern Virginia Medical School.

Dr. Lai will assume the role of CMC (Chemistry, Manufacturing, and Controls) advisor having spent years handling process and product development activities, for portfolio vaccine products in the preclinical stage, progressing into clinical stages in various pharmaceutical companies. Dr. Lai obtained her Ph.D. from the University of Cambridge and a First Class Honours in B. Eng (Chemical) from the National University of Singapore. She later received her MBA from the Singapore Management University, where she graduated as valedictorian. 

 

Together, these two industry veterans will lend their business, technology, and operational acumen to support the PathoVax team to develop and push forward our innovative programs. 

PathoVax secures $2.75M

October 17, 2018

We are pleased to announce our $2.75M raise! This round will support our continued commitment to bringing our universal HPV vaccine one step closer to the clinic!

US$30K Award at the 4th Annual China-US Innovation Competition + China Visit (Jul-20 to Aug-5)

June 08, 2018

At the 4th annual China-US Innovation Competition hosted by the Entrepreneur Foundation, PathoVax won the US$30k First Place prize award and a fully-sponsored networking trip to six major cities in China (Beijing, Shandong, Shanghai, Hefei, Hangzhou and Guangzhou) from July-20 to August-5. Get in touch if you are interested to learn more about the first universal HPV vaccine! 

 

https://www.prnewswire.com/news-releases/the-4th-annual-china-us-innovation-competition-hosted-by-the-entrepreneur-foundation-300660649.html

PathoVax Secures NSF SBIR phase 1 and NIAID SBIR Fast-track awards worth $2.3M

January 02, 2019

PathoVax has been awarded TWO more SBIR grants (~$2.3M USD in total) from the National Institute of Allergy and Infectious Diseases (NIAID) as well as the National Science Foundation (NSF) to advance our Human Papillomavirus Virus-like particles for both infectious diseases and cancer!! This was featured in the Baltimore Business Journal. Click below to find out more!

PathoVax awarded NIH STTR Phase 1 grant worth $300K

September 21, 2017

We are pleased to announce that PathoVax LLC has been awarded a Phase 1 STTR grant by the National Institutes of Health entitled "Polyionic Papillomavirus-like Particles (VLP) for the Treatment of HPV+ oropharyngeal squamous cell carcinomas (OPCs)". This grant will allow PathoVax to continue demonstrating that their patented HPV VLPs are robust carriers for novel antigens to induce targeted immune responses against cancer and infectious diseases!

PathoVax featured on Buffalo Business First

May 26, 2017

Thanks to Buffalo Business First for covering our experiences alongside with 43North!

We remain committed to solving the HPV epidemic with our RGVax vaccine as well as investigating new promising cancer therapies with our VLP platform with both the University of Buffalo & Roswell Park Cancer Institute!

Finalist for the 2017 Start-Up Stadium event at the BIO International Convention

May 11, 2017

​As the world’s largest biotechnology event, the Start-Up Stadium at the BIO International Convention was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees. As a finalist, PathoVax will receive live feedback from investors on our 5-7 minute pitch.

PathoVax wins best pitch at the 2017 NYBIO conference!

May 01, 2017

Out of 70 companies, PathoVax won best pitch at the 2017 NYBIO conference/Pitchfest! Winning this event provides a reimbursement of up to $2,000 of direct expenses associated with attending the upcoming International Bio convention! See you in San Diego! 

Buffalo, NY recognizes PathoVax as a $500K winner!

October 27, 2016

As part of Governor Andrew Cuomo’s Buffalo Billion initiative, the 43North competition features a grand prize of $1 million, a runner-up prize of $600,000, and six $500,000 awards. On Oct-27, PathoVax received a $500,000 prize award, in addition to free incubator space in Buffalo for one year, guidance from mentors in related fields, and access to more business incentive programs such as START-UP NY.

PathoVax was featured in The Straits Times Singapore!

October 11, 2016

PathoVax was featured in The Straits Times as part of a series on "Winning the battle against Cervical cancer in Singapore"

PathoVax featured in Biotech In Asia

August 10, 2016

Thanks to @biotechinasia for the feature! We're excited to contribute to the biotech entrepreneurship ecosystem in both USA & Asia!

PathoVax is one of the top 128 finalists for the 2016 MassChallenge accelerator program in Boston

May 19, 2016

PathoVax recognized as OneStart Americas’ top-10 healthcare startups of 2016

April 25, 2016

After eight weeks of intense mentoring with industry executives from SR One and Johnson & Johnson Innovation, PathoVax was announced as the top-10 finalists for OneStart Americas' 2016. On May-26, PathoVax will pitch our next-gen HPV vaccine technology in front of top biopharmaceutical veterans from SR One, Takeda Ventures, Bristol-Myers Squibb and Sanofi  for the grand prize of $150,000 and lab space. Join us at the grand gala dinner in Boston!

PathoVax begins the 2016 MassCONNECT program with three other promising biotech upstarts

February 29, 2016

PathoVax took part in a Technology Showcase at the MassBio head office, presenting to industry executives and potential mentors to get early feedback. Over the course of eight weeks, PathoVax will continue to get feedback from designated mentors before making presentations to venture capitalists and potential partners.

PathoVax accepted into the Venture Incubation Program at Harvard Innovation Lab

January 15, 2016

Joining the list of startups who have gone on to great success, PathoVax has been granted access to resources and contacts at Harvard Innovation Lab. PathoVax is looking forward to learning from the Boston community! 

 

PathoVax selected as OneStart Americas 2016 Semi-finalist

December 22, 2015

PathoVax is one of the 80 Semi-Finalists (top 10% of over 750 teams worldwide) for the 2016 OneStart Competition - the world's largest life sciences and healthcare startup accelerator program. We are truly excited to be a part of the OneStart BioTech Bootcamp in SF this February 2016 and share PathoVax's mission with leading pharmaceutical executives.

 

PathoVax named 2015 "Best of the Best" at finals of 1st Pitch Life Sciences Competition.

December 07, 2015

Shortly after winning "Best in Show" at the 1st Pitch Life Sciences Competition in New Jersy this November, PathoVax headed up to the New York Genome Center in Manhattan, NYC in early December for the 2015 1st Pitch Life Sciences Best of the Best competition. This final competition pitted previous “Best in Show” winners from New York, New Jersey and Philadelphia competitions throughout 2015. PathoVax is pleased to have triumphed over a field of six previous “Best In Show” winners and named as “Best of the Best” of 2015.

 

“Best in Show” at 1st Pitch Life Science New Jersey Competition

November 24, 2015

Mid-Atlantic Bio Angels (MABA) announces that PathoVax, LLC. was named “Best in Show” at MABA’s 1st Pitch Life Science New Jersey event on November 11, 2015. Joshua Wang, PhD, made a "...well-thought-out, concise and engaging presentation in support of their RGVax HPV vaccine and easily earned the “Best In Show” award." according to Yaniv Sneor, MABA co-founder.

 

Winner: Innovation Day at Harvard's Healthcare Innovation and Commercialization Workshop

November 10, 2015

PathoVax's innovation RGVax technology was the top winner at the Innovation Day as part of the Healthcare Innovation and Commercialization (HIC) workship. RGVax was one of five disruptive technologies selected for teams to work on and Weijie Poh, PathoVax co-founder (fourth from right), pitched to judges from angel investor groups and venture capital firms: Richard Anders (Mass Medical Angels), Ari Brettman, MD (Clarus Ventures) and Gladys Nunez, MS. (Amgen Ventures).

 

Semi-Finalist: 2015 Arch Grants Global Startup Competition

August 05, 2015

PathoVax has been selected for the final round of the ArchGrants global startup competition! We will be battling against 29 other teams for 10 spots that will receive a $50,000 prize and a number of startup assistance services. Co-founder Nick Calcaterra will be back in his hometown of Saint Louis to pitch for PathoVax!

 

PathoVax congratulates Prof Roden on $100,000 Maryland Innovation Initiative grant award

July 01, 2015

PathoVax scientific advisor and RGVax co-inventor, Richard Roden, PhD at Johns Hopkins School of Medicine and members of the PathoVax team were just awarded $100,000 from TEDCO via the Maryland Innovation Initiative (MII)! This grant allows our team to begin groundbreaking research on making cutting edge HPV vaccines that have the potential to eradicate HPV by preventing all 120+ types that cause disease in humans. Another step forward in blazing the trail to complete protection!

 

First Place (Medical Technology, Graduate Track), JHU Business Plan Competition

May 01, 2015

PathoVax won the top prize in the Medical Technology, Graduate category at the JHU Business Plan competition! We are honored to have another validation that the RGVax technology will revolutionize public health and will be using the $10,000 award to drive development of this groundbreaking innovation!

 

Please reload